Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
35 studies found for:    Open Studies | "Endometrial Neoplasms"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Unknown  Tissue Bank of Biological Specimens From Patients With Gynecologic Disease
Conditions: Endometrial Neoplasms;   Uterine Cervical Neoplasms;   Ovarian Neoplasms;   Leiomyoma
Intervention:
2 Recruiting The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma
Condition: Endometrial Neoplasms
Interventions: Drug: Paclitaxel;   Drug: Paraplatin (Carboplatin Injection);   Radiation: Pelvic Radiation;   Radiation: Vaginal Brachytherapy 1;   Radiation: Vaginal brachytherapy 2
3 Not yet recruiting Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma
Condition: Endometrial Neoplasms
Intervention: Drug: Ponatinib
4 Unknown  Questionnaire Study for Gynecological Cancer Survivors
Conditions: Endometrial Neoplasms;   Ovarian Neoplasms;   Uterine Cervical Neoplasms;   Vulvar Neoplasms;   Vaginal Neoplasms;   Genital Neoplasms, Female
Intervention: Behavioral: Psychosocial
5 Recruiting Robotic Versus Abdominal Surgery for Endometrial Cancer
Condition: Endometrial Neoplasms
Interventions: Procedure: Robotic surgery;   Procedure: Abdominal surgery
6 Recruiting Molecular Markers in Treatment in Endometrial Cancer
Conditions: Endometrial Neoplasms;   Neoplasm Metastasis
Intervention: Procedure: Tumor biopsy study
7 Recruiting [F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers
Conditions: Uterine Cervical Neoplasms;   Endometrial Neoplasms;   Anus Neoplasms;   Rectal Neoplasms;   Prostatic Neoplasms
Intervention: Radiation: Bone marrow sparing IMRT radiation therapy
8 Recruiting STELLA Trial: Transperitoneal vs. Extraperitoneal Approach for Laparoscopic Staging of Endometrial/Ovarian Cancer
Conditions: Endometrial Neoplasms;   Ovarian Neoplasms
Interventions: Procedure: Transperitoneal laparoscopic aortic lymphadenectomy;   Procedure: Extraperitoneal laparoscopic aortic lymphadenectomy
9 Unknown  Early Detection of Cancers in Low Resource Countries
Conditions: Breast Neoplasms;   Uterine Cervical Neoplasms;   Ovarian Neoplasms;   Endometrial Neoplasms
Interventions: Procedure: Breast Cancer Screening and Diagnosis;   Procedure: Cervical Cancer Screening and Diagnosis;   Procedure: Ovarian Cancer Screening and Diagnosis;   Procedure: Endometrial Cancer Screening and Diagnosis
10 Recruiting Genetic Pap Test for Endometrial and Ovarian Cancers
Conditions: Ovarian Neoplasms;   Endometrial Neoplasms
Intervention:
11 Recruiting The Safety of Ovarian Preservation in Stage IA Endometrial Carcinoma
Condition: Endometrial Neoplasms
Interventions: Procedure: TH;   Procedure: TH/BSO;   Procedure: BPLND
12 Unknown  Letrozole as a Treatment of Endometrial Cancer
Condition: Endometrial Carcinoma
Intervention: Drug: Letrozole
13 Recruiting Effect of Curcumin Addition to Standard Treatment on Tumour-induced Inflammation in Endometrial Carcinoma
Condition: Endometrial Carcinoma
Intervention: Dietary Supplement: Curcuphyt
14 Recruiting Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA
Condition: Recurrent or Persistent Endometrial Carcinoma
Intervention: Drug: Sodium cridanimod
15 Recruiting Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
Conditions: Recurrent Endometrial Carcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Stage IIIA Endometrial Carcinoma;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Endometrial Carcinoma;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Endometrial Carcinoma;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer;   Stage IVA Endometrial Carcinoma;   Stage IVB Endometrial Carcinoma
Interventions: Procedure: therapeutic conventional surgery;   Drug: cisplatin;   Drug: carboplatin;   Drug: paclitaxel;   Drug: pegylated liposomal doxorubicin hydrochloride;   Drug: gemcitabine hydrochloride;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis
16 Not yet recruiting Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
Conditions: Recurrent Endometrial Carcinoma;   Stage III Endometrial Carcinoma;   Stage IV Endometrial Carcinoma
Intervention: Other: laboratory biomarker analysis
17 Unknown  Risk Factors for Concurrent Endometrial Carcinoma in Patients With a Curettage Diagnosis of Endometrial Hyperplasia
Condition: Endometrial Carcinoma
Intervention:
18 Recruiting Lymph Node Mapping in Patients With Newly Diagnosed Endometrial Cancer Undergoing Surgery
Conditions: Stage I Endometrial Carcinoma;   Stage II Endometrial Carcinoma;   Stage III Endometrial Carcinoma;   Stage IV Endometrial Carcinoma
Interventions: Procedure: lymph node mapping;   Procedure: sentinel lymph node biopsy;   Drug: isosulfan blue;   Drug: indocyanine green solution;   Procedure: therapeutic conventional surgery;   Procedure: lymphadenectomy
19 Recruiting Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Brenner Tumor;   Ovarian Carcinosarcoma;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Serous Surface Papillary Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Drug: WEE1 Inhibitor MK-1775;   Drug: Gemcitabine Hydrochloride;   Other: Placebo;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
20 Recruiting Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Brenner Tumor;   Ovarian Carcinosarcoma;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Stage II Ovarian Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer;   Undifferentiated Ovarian Carcinoma
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Biological: Bevacizumab;   Drug: Veliparib;   Drug: Cisplatin;   Other: Laboratory Biomarker Analysis

   Previous Page Studies Shown (1-20) Next Page (21-35) Show next page of results    Last Page
Indicates status has not been verified in more than two years